FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
4D Molecular Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$12.29+0.15 (+1.24%)
Close on Oct 19, 2026
- Market cap
- $863.64M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
80.5%
58M of 72M shares
Institutional holders
158
31 new, 24 sold out
Net institutional buying
13M
In Q2 2026
Insider trades, 12 months
0 buys · 23 sales
Net sold $4.61M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bvf Inc/Il | 5,847,281 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Rajeev Shah | 5,713,852 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Lampert Mark N | 5,346,519 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Janus Henderson Group PLC | 5,247,151 | 10.30% | 13G (passive) amendment | Mar 31, 2026 |
| RA Capital Management, L.P. | 5,105,622 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Bvf Partners L P/Il | 4,834,297 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| Peter Kolchinsky | 4,564,867 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| The Goldman Sachs Group, Inc. | 4,423,435 | 9.60% | 13G (passive) amendment | Dec 31, 2024 |
| Goldman Sachs & Co. LLC | 4,286,077 | 7.50% | 13G (passive) amendment | Dec 31, 2025 |
| Novo Holdings A/S | 3,650,737 | 6.40% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 3,062,596 | 6.60% | 13G (passive) amendment | Sep 30, 2025 |
| Venrock Healthcare Capital Partners EG, L.P. | 2,952,371 | 6.40% | 13G (passive) amendment | Dec 31, 2024 |
| State Street Corporation | 2,707,875 | 5.30% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FDMT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 5,746,289 | 7.96% | $76.47M | New | 0.03% |
| Ra Capital Management, L.P. | 5,049,779 | 7.00% | $67.16M | – | 0.58% |
| BlackRock, Inc. | 4,546,059 | 6.30% | $60.46M | +400,756 | 0.00% |
| Goldman Sachs Group Inc | 4,258,668 | 5.90% | $56.64M | +53,230 | 0.00% |
| Novo Holdings A/S | 3,249,178 | 4.50% | $43.21M | −401,559 | 2.51% |
| State Street Corp | 2,911,109 | 4.03% | $38.72M | +203,234 | 0.00% |
| Bvf Inc/Il | 2,879,289 | 3.99% | $38.29M | – | 0.98% |
| T. Rowe Price Investment Management, Inc. | 2,511,887 | 3.48% | $33.41K | New | 0.02% |
| Adage Capital Partners Gp, L.L.C. | 2,249,203 | 3.12% | $29.91M | +644,047 | 0.04% |
| Trails Edge Capital Partners, LP | 2,227,917 | 3.09% | $29.63M | +925,000 | 4.70% |
| Vanguard Capital Management LLC | 2,099,055 | 2.91% | $27.92M | −96,523 | 0.00% |
| Armistice Capital, LLC | 2,000,000 | 2.77% | $26.60M | – | 0.33% |
| Geode Capital Management, LLC | 1,128,466 | 1.56% | $15.01M | +63,121 | 0.00% |
| Bank Of America Corp /De/ | 1,120,674 | 1.55% | $14.90M | +146,501 | 0.00% |
| Evergreen Quality Fund GP, Ltd. | 951,474 | 1.32% | $12.65M | – | 0.20% |
| Parkman Healthcare Partners LLC | 948,184 | 1.31% | $12.61M | +425,607 | 1.29% |
| Dimensional Fund Advisors LP | 730,857 | 1.01% | $9.72M | +208,034 | 0.00% |
| Deutsche Bank AG\ | 710,942 | 0.98% | $9.46M | +2,898 | 0.00% |
| Citadel Advisors LLC | 687,597 | 0.95% | $9.15M | +423,501 | 0.00% |
| Renaissance Technologies LLC | 614,573 | 0.85% | $8.17M | +36,308 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 158 | 58M | 80.5% | 31 / 63 | 37 / 24 | 16M | 3M |
| Q1 2026 | 153 | 51M | 70.2% | 28 / 39 | 49 / 26 | 8M | 8M |
| Q4 2025 | 153 | 53M | 74.0% | 32 / 56 | 37 / 12 | 17M | 3M |
| Q3 2025 | 134 | 40M | 55.5% | 33 / 32 | 47 / 19 | 3M | 3M |
| Q2 2025 | 120 | 41M | 56.2% | 17 / 43 | 40 / 22 | 3M | 5M |
| Q1 2025 | 125 | 43M | 59.7% | 18 / 32 | 58 / 37 | 6M | 10M |
| Q4 2024 | 145 | 47M | 64.9% | 32 / 50 | 46 / 27 | 5M | 17M |
| Q3 2024 | 140 | 59M | 81.1% | 23 / 57 | 43 / 25 | 14M | 9M |
| Q2 2024 | 143 | 58M | 79.9% | 29 / 54 | 37 / 32 | 5M | 7M |
| Q1 2024 | 147 | 60M | 82.9% | 54 / 49 | 37 / 18 | 20M | 4M |
| Q4 2023 | 111 | 44M | 61.6% | 20 / 44 | 27 / 19 | 6M | 3M |
| Q3 2023 | 110 | 42M | 58.1% | 20 / 42 | 33 / 10 | 3M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of FDMT | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,608,619 | 2.23% | $21.39M | 0.20% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,588,533 | 2.20% | $21.13M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,183,771 | 1.64% | $15.74M | 0.02% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 788,444 | 1.09% | $10.49M | 0.18% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 681,919 | 0.94% | $9.07M | 0.10% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 501,536 | 0.69% | $5.11M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 460,479 | 0.64% | $6.12M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 455,274 | 0.63% | $6.06M | 0.06% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 412,658 | 0.57% | $5.49M | 0.04% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 388,800 | 0.54% | $3.96M | 0.10% | Jul 31, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 368,160 | 0.51% | $4.90M | 0.10% | Jun 30, 2026 |
| iShares Biotechnology ETF | 329,017 | 0.46% | $4.38M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 275,621 | 0.38% | $3.67M | 0.13% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 226,579 | 0.31% | $2.25M | 0.01% | May 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 209,243 | 0.29% | $2.13M | 0.10% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David Kirn | See Remarks, Director | 1,367,486 | 1.89% | Sep 16, 2026 |
| Scott Bizily | Chief Legal Officer | 8,617 | 0.01% | Sep 22, 2026 |
| Christopher Paul Simms | See Remarks | – | – | Mar 27, 2026 |
| Ashoo Gupta | VP, Finance and Controller | 47,055 | 0.07% | Mar 24, 2026 |
| Kristian Humer | Chief Financial Officer | – | – | Dec 11, 2025 |
| Robert Young Kim | Chief Medical Officer | 1,595 | 0.00% | Mar 10, 2025 |
| Uneek Mehra | See Remarks | – | – | Mar 10, 2025 |
| Fariborz Kamal | President & COO | 4,347 | 0.01% | Mar 10, 2025 |
| Susannah Gray | Director | – | – | Jun 18, 2026 |
| John F. Milligan | Director | 100,000 | 0.14% | Jun 18, 2026 |
| Shawn Tomasello | Director | – | – | Jun 18, 2026 |
| Nancy Miller-Rich | Director | – | – | Jun 18, 2026 |
| Glenn Sblendorio | Director | – | – | Jun 18, 2026 |
| Charles Theuer | Director | 41,684 | 0.06% | Jun 18, 2026 |
| Jacob Chacko | Director | 0 | – | Jun 18, 2026 |
| Capital Healthcare Fund LP RA | 10% owner | – | – | Dec 10, 2024 |
| Rajeev M. Shah | 10% owner | – | – | Dec 10, 2024 |
| Peter Kolchinsky | 10% owner | – | – | Dec 10, 2024 |
| Ra Capital Management, L.P. | 10% owner | 4,563,211 | 6.32% | Dec 10, 2024 |
| Ii Gp Llc Bvf | – | – | – | Nov 13, 2024 |
| Partners OS Ltd. BVF | – | 1,570,857 | 2.18% | Nov 13, 2024 |
| Value Fund L. P. Biotechnology | – | – | – | Nov 13, 2024 |
| Partners L. P/Il Bvf | – | – | – | Nov 13, 2024 |
| Value Trading Fund OS LP Biotechnology | – | – | – | Nov 13, 2024 |
| Mark N. Lampert | – | – | – | Nov 13, 2024 |
| Value Fund Ii Lp Biotechnology | – | – | – | Nov 13, 2024 |
| I. Gp Llc Bvf | – | 662,970 | 0.92% | Nov 13, 2024 |
| Inc/Il Bvf | – | 3,040,970 | 4.21% | Nov 13, 2024 |
| Gp Holdings Llc Bvf | – | – | – | Nov 13, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Scott Bizily Chief Legal Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −1,635 | $13.65 | $22.32K | 8,617 |
| Scott Bizily Chief Legal Officer | Sep 16, 2026 | Option exercise | +1,635 | $4.14 | $6.77K | 10,252 |
| David Kirn See Remarks, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −58,333 | $13.90 | $810.83K | 767,486 |
| Scott Bizily Chief Legal Officer | Sep 1, 2026 | Option exercise | +584 | $6.49 | $3.79K | 9,201 |
| Scott Bizily Chief Legal Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −584 | $14.00 | $8.18K | 8,617 |
| David Kirn See Remarks, Director | Aug 19, 2026 | Option exercise | +50,000 | $4.14 | $207.00K | 894,895 |
| David Kirn See Remarks, Director | Aug 19, 2026 | Sale(10b5-1 plan) | −25,927 | $16.42 | $425.72K | 825,819 |
| David Kirn See Remarks, Director | Aug 19, 2026 | Sale(10b5-1 plan) | −43,149 | $15.36 | $662.77K | 851,746 |
| Scott Bizily Chief Legal Officer | Aug 17, 2026 | Option exercise | +1,635 | $4.14 | $6.77K | 10,252 |
| Scott Bizily Chief Legal Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −1,635 | $12.20 | $19.95K | 8,617 |
| Scott Bizily Chief Legal Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −1,635 | $12.00 | $19.62K | 8,617 |
| Scott Bizily Chief Legal Officer | Aug 13, 2026 | Option exercise | +1,635 | $4.14 | $6.77K | 10,252 |
| David Kirn See Remarks, Director | Aug 4, 2026 | Sale(10b5-1 plan) | −26,842 | $10.23 | $274.59K | 844,895 |
| David Kirn See Remarks, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −12,415 | $10.05 | $124.77K | 871,737 |
| David Kirn See Remarks, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −442 | $12.84 | $5.68K | 884,152 |
| David Kirn See Remarks, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −15,283 | $12.01 | $183.55K | 884,594 |
| David Kirn See Remarks, Director | Jul 9, 2026 | Sale(10b5-1 plan) | −42,608 | $12.87 | $548.36K | 899,877 |
| Scott Bizily Chief Legal Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −6,566 | $14.00 | $91.92K | 8,617 |
| Scott Bizily Chief Legal Officer | Jun 30, 2026 | Option exercise | +814 | $4.14 | $3.37K | 9,431 |
| Scott Bizily Chief Legal Officer | Jun 30, 2026 | Option exercise | +5,752 | $6.49 | $37.33K | 15,183 |
| Scott Bizily Chief Legal Officer | Jun 23, 2026 | Option exercise | +9,810 | $4.14 | $40.61K | 18,427 |
| Scott Bizily Chief Legal Officer | Jun 23, 2026 | Sale(10b5-1 plan) | −9,810 | $12.00 | $117.72K | 8,617 |
| David Kirn See Remarks, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −114,746 | $10.47 | $1.20M | 942,485 |
| David Kirn See Remarks, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −1,922 | $10.02 | $19.26K | 1,057,231 |
| Ashoo Gupta VP, Finance and Controller | Mar 20, 2026 | Sale | −80 | $8.61 | $689 | 47,055 |
| Ashoo Gupta VP, Finance and Controller | Mar 20, 2026 | Option exercise | +221 | – | – | 47,135 |
| Ashoo Gupta VP, Finance and Controller | Mar 20, 2026 | Option exercise | +865 | – | – | 47,224 |
| Ashoo Gupta VP, Finance and Controller | Mar 20, 2026 | Sale | −310 | $8.61 | $2.67K | 46,914 |
| Ashoo Gupta VP, Finance and Controller | Dec 20, 2025 | Option exercise | +866 | – | – | 46,528 |
| Ashoo Gupta VP, Finance and Controller | Dec 20, 2025 | Sale | −79 | $8.68 | $686 | 46,359 |
| Ashoo Gupta VP, Finance and Controller | Dec 20, 2025 | Option exercise | +220 | – | – | 46,438 |
| Ashoo Gupta VP, Finance and Controller | Dec 20, 2025 | Sale | −310 | $8.68 | $2.69K | 46,218 |
| Scott Bizily Chief Legal Officer | Dec 16, 2025 | Sale(10b5-1 plan) | −1,635 | $10.90 | $17.82K | 3,594 |
| Scott Bizily Chief Legal Officer | Dec 16, 2025 | Option exercise | +1,635 | $4.14 | $6.77K | 5,229 |
| Charles Theuer Director | Dec 12, 2025 | Option exercise | +9,333 | $1.14 | $10.64K | 41,684 |
| Scott Bizily Chief Legal Officer | Nov 17, 2025 | Sale(10b5-1 plan) | −1,635 | $10.59 | $17.31K | 3,594 |
| Scott Bizily Chief Legal Officer | Nov 17, 2025 | Option exercise | +1,635 | $4.14 | $6.77K | 5,229 |
| Scott Bizily Chief Legal Officer | Oct 24, 2025 | Sale(10b5-1 plan) | −2,678 | $12.00 | $32.14K | 3,594 |
| Scott Bizily Chief Legal Officer | Oct 24, 2025 | Option exercise | +1,084 | $6.49 | $7.04K | 6,272 |
| Scott Bizily Chief Legal Officer | Oct 16, 2025 | Sale(10b5-1 plan) | −1,635 | $10.17 | $16.63K | 5,188 |
| Scott Bizily Chief Legal Officer | Oct 16, 2025 | Option exercise | +1,635 | $4.14 | $6.77K | 6,823 |
| Scott Bizily Chief Legal Officer | Oct 9, 2025 | Sale(10b5-1 plan) | −2,408 | $10.00 | $24.08K | 5,188 |
| Scott Bizily Chief Legal Officer | Sep 23, 2025 | Sale(10b5-1 plan) | −2,407 | $8.00 | $19.26K | 7,596 |
| Ra Capital Management, L.P. 10% owner | Dec 9, 2024 | Other | −535,000 | – | – | 4,563,211 |
| I. Gp Llc Bvf – | Nov 8, 2024 | Other | −2,378,000 | – | – | 662,970 |
| I. Gp Llc Bvf – | Nov 8, 2024 | Other | −240,000 | – | – | 87,911 |
| I. Gp Llc Bvf – | Nov 8, 2024 | Other | −3,062,000 | – | – | 830,237 |
| Scott Bizily Chief Legal Officer | Sep 16, 2024 | Option exercise | +500 | $6.49 | $3.25K | 7,281 |
| Scott Bizily Chief Legal Officer | Sep 16, 2024 | Sale(10b5-1 plan) | −500 | $16.33 | $8.17K | 6,781 |
| Scott Bizily Chief Legal Officer | Aug 19, 2024 | Sale(10b5-1 plan) | −500 | $15.00 | $7.50K | 6,781 |
| Scott Bizily Chief Legal Officer | Aug 19, 2024 | Option exercise | +500 | $6.49 | $3.25K | 7,281 |
| Scott Bizily Chief Legal Officer | Jul 16, 2024 | Option exercise | +500 | $6.49 | $3.25K | 7,281 |
| Scott Bizily Chief Legal Officer | Jul 16, 2024 | Option exercise | +1,250 | $8.04 | $10.05K | 8,531 |
| Scott Bizily Chief Legal Officer | Jul 16, 2024 | Sale(10b5-1 plan) | −1,750 | $27.11 | $47.44K | 6,781 |
| Scott Bizily Chief Legal Officer | Jul 11, 2024 | Option exercise | +1,996 | $15.78 | $31.50K | 8,777 |
| Scott Bizily Chief Legal Officer | Jul 11, 2024 | Sale(10b5-1 plan) | −1,996 | $25.00 | $49.90K | 6,781 |
| David Kirn Chief Executive Officer, Director | Jul 10, 2024 | Sale(10b5-1 plan) | −12,923 | $22.49 | $290.64K | 1,059,153 |
| David Kirn Chief Executive Officer, Director | Jul 10, 2024 | Option exercise | +1,270 | $15.78 | $20.04K | 1,072,076 |
| David Kirn Chief Executive Officer, Director | Jul 10, 2024 | Option exercise | +11,653 | $14.42 | $168.04K | 1,070,806 |
| Scott Bizily Chief Legal Officer | Jul 1, 2024 | Option exercise | +2,916 | $8.04 | $23.44K | 5,985 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kirn David Officer | Oct 5, 2026 | 58,333 | $753.66K | Oct 5, 2026 | Acquired from issuer in private transaction |
| Kirn David Officer | Sep 14, 2026 | 58,333 | $802.66K | Sep 14, 2026 | Acquired from issuer in private transaction |
| Kirn David Officer | Aug 19, 2026 | 69,076 | $1.16M | Aug 19, 2026 | Acquired from issuer in private transaction |
| Bizily Scott Officer | Aug 17, 2026 | 6,540 | $79.72K | Aug 17, 2026 | Exercise of Stock Options |
| Bizily Scott Officer | Aug 13, 2026 | 1,635 | $19.41K | Aug 13, 2026 | Exercise of Stock Options |
| Kirn David Officer | Aug 4, 2026 | 26,842 | $275.40K | Aug 4, 2026 | Acquired from issuer in private transaction |
| Kirn David Officer | Aug 3, 2026 | 12,415 | $125.27K | Aug 3, 2026 | Acquired from issuer in private transaction |
| Kirn David Officer | Jul 10, 2026 | 15,725 | $193.57K | Jul 10, 2026 | Acquired from issuer in private transaction |
| Kirn David Officer | Jul 9, 2026 | 42,608 | $549.22K | Jul 9, 2026 | Acquired from issuer in private transaction |
| Bizily Scott Officer | Jun 30, 2026 | 6,566 | $84.57K | Jun 30, 2026 | Exercise of Stock Options |
| Bizily Scott Officer | Jun 23, 2026 | 9,810 | $102.22K | Jun 23, 2026 | Exercise of Stock Options |
| Kirn David Officer | Jun 22, 2026 | 114,746 | $1.20M | Jun 22, 2026 | Acquired from issuer in private transaction |
| Kirn David Officer | Jun 1, 2026 | 1,922 | $18.66K | Jun 1, 2026 | Acquired from issuer in private transaction |
| Bizily Scott Officer | Dec 16, 2025 | 1,635 | $17.90K | Dec 16, 2025 | Exercise of Stock Options |
| Bizily Scott Officer | Nov 17, 2025 | 1,635 | $17.64K | Nov 17, 2025 | Exercise of Stock Options |